Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

INTRODUCTION: This study explored the safety and tolerability features of donanemab (LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild to moderate AD dementia. METHODS: Patients with AD were enrolled into the single‐ascending dose phase and were admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowe, Stephen Loucian, Willis, Brian A., Hawdon, Anne, Natanegara, Fanni, Chua, Laiyi, Foster, Joanne, Shcherbinin, Sergey, Ardayfio, Paul, Sims, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882532/
https://www.ncbi.nlm.nih.gov/pubmed/33614890
http://dx.doi.org/10.1002/trc2.12112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882532/
https://www.ncbi.nlm.nih.gov/pubmed/33614890
http://dx.doi.org/10.1002/trc2.12112

Ejemplares similares